One of the reasons why cancer is so hard to treat is that the body has a hard time identifying cancerous cells. IN8bio, Inc. (Nasdaq: INAB) seeks to solve this issue through gamma-delta T cell therapy, which assists the body in identifying cancerous cells and targeting them with a thorough immune response. Does that make it unique among biotech stocks? No. There...
IN8bio ssould continue it's downward spiraling channel play. Traded it a few times already.
Expect it to go down to the $5.20 - $5 for a reasonable enrty into a long position (back up to the top channel).
There is no social media buzz, the company seems relatively unknown.
Volume here is tiny, positions have to be small or you'll end up trapped. Risky...
